Docetaxel in the treatment of advanced breast cancer / 中华肿瘤杂志
Chinese Journal of Oncology
; (12): 468-470, 2006.
Article
Dans Zh
| WPRIM
| ID: wpr-236914
Responsable en Bibliothèque :
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy, toxicity and safety of an new domestic docetaxel in the treatment of pretreated advanced breast cancer.</p><p><b>METHODS</b>Fourty-four breast cancer patients who had failed in first-line chemotherapy were included in this trial. They received docetaxel as the second-line chemotherapy. Docetaxel was administered alone at a dose of 70 mg/m2 every 3 weeks. The use of granulocyte colony-stimulating factor to prevent granulocytopenia was not permitted. The response rate and toxicity were evaluated by World Health Organization toxicity scale and performance status by Karnofsky scale.</p><p><b>RESULTS</b>Of the 41 evaluable patients, 4 achieved complete response and 14 partial remission, with a response rate and clinical benefit rate of 43.9% and 85.4%, respectively. Grade 3 or grade 4 neutropenia developed in 42.9%, alopecia in 7.1% and vomiting in 4.8% of these patients. Fluid retention was not observed in this series.</p><p><b>CONCLUSION</b>Three-week administration of docetaxel alone at a dose of 70 mg/m2 is effective and tolerable. It provides an alternative for the pretreated advanced breast cancer patients.</p>
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Anatomopathologie
/
Vomissement
/
Induction de rémission
/
Tumeurs du sein
/
Résultat thérapeutique
/
Taxoïdes
/
Utilisations thérapeutiques
/
Traitement médicamenteux
/
Alopécie
/
Stadification tumorale
Limites du sujet:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
langue:
Zh
Texte intégral:
Chinese Journal of Oncology
Année:
2006
Type:
Article